Hepatitis B virus (HBV) infection is a serious global health problem, with 2 billion people
infected worldwide, and 350 million suffering from chronic HBV infection. The 10th leading …

Chronic hepatitis B is caused by persistent infection with the hepatitis B virus (HBV), a
unique DNA virus that replicates through an RNA intermediate produced from a stable …

Chronic infection with the hepatitis B virus (HBV) is estimated to affect 400 million persons
and to be the single most common cause of cirrhosis and hepatocellular carcinoma (HCC) …

Publisher Summary An increasing number of treatment failures because of antiviral
resistance have been recognized since the introduction of antiviral agents, such as …

Highlights•Five nucleoside inhibitors of HBV polymerase have been approved for clinical
use.•HBV polymerase protein priming activity is inhibited by purine analogs.•Entecavir and …

After receiving lamivudine for 3 years to treat chronic hepatitis B, 67–75% of patients
develop B-domain L528M, C-domain M552I, or M552V mutations in the HBV polymerase …

Success in treating hepatitis B virus (HBV) infection with nucleoside analog drugs like
lamivudine is limited by the emergence of drug-resistant viral strains upon prolonged …

Lamivudine therapy induces improvements in chronic hepatitis B in a high proportion of
patients, but prolonged therapy is limited by the development of viral resistance. We …

Uncontrolled studies have suggested a beneficial effect of lamivudine in patients with
decompensated cirrhosis caused by replicating hepatitis B virus (HBV). We analyzed the …

The potential for hepatitis B virus (HBV) to alter its genome is considerable. This occurs
because the virus utilizes a reverse transcription step in replicating the viral genome. Like …